Navigation Links
Ventas Announces 2008 First Quarter Earnings Release Date and Conference Call
Date:4/8/2008

LOUISVILLE, Ky., April 8, 2008 /PRNewswire-FirstCall/ -- Ventas, Inc. (NYSE: VTR) ("Ventas" or the "Company") announced today that it will issue its 2008 first quarter earnings release after the close of trading on Tuesday, May 6, 2008. A conference call to discuss those earnings will be held on Wednesday, May 7, 2008 at 10:00 a.m. Eastern Time (9:00 a.m. Central Time). The call will be webcast live by CCBN and can be accessed at the Company's website at http://www.ventasreit.com or at http://www.earnings.com.

Ventas, Inc. is a leading healthcare real estate investment trust. Its diverse portfolio of properties located in 43 states and two Canadian provinces includes seniors housing communities, skilled nursing facilities, hospitals and medical office and other properties. More information about Ventas can be found on its website at http://www.ventasreit.com.

Contacts: Debra A. Cafaro

Chairman, President and CEO

or

Richard A. Schweinhart

Executive Vice President and CFO

(502) 357-9000


'/>"/>
SOURCE Ventas, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1

Related medicine news :

1. Ventas to Present at Credit Suisse 2008 Global Real Estate Conference
2. Ventas Announces Brush Departure
3. Ventas Appoints James D. Shelton and Robert D. Reed to Board
4. Ventas to Present at the Citi 2008 Global Property CEO Conference
5. Ventas Reports Ten Percent Rise in 2007 Normalized FFO Per Common Share to $2.69
6. Ventas Completes Previously Announced Sale of Common Stock
7. Ventas Enters Agreement to Sell Common Stock
8. Ventas Grants Stock Awards to Promote Long-Term Retention and Reward Performance
9. Ventas Declares Regular Quarterly Dividend of $0.475 Per Share
10. Ventas Appoints Brush SVP - Senior Housing Development and Operations
11. Ventas Announces 2007 Third Quarter Earnings Release Date and Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2008)...chnique to combat cancer, study says, , ...esearchers have discovered that some cancer cells ...s might lead to new treatments that starve and kil...l cells in the body need to produce energy. They d...requires oxygen. Compared with normal cells, tumor...
(Date:11/21/2008)...rsingCenter.com, the premier site,for online nurs..., has been,updated to improve the interactive exp... by Lippincott Williams & Wilkins (LWW), Nursi...continuing education activities and free,access t...g journals.,Lippincott Williams & Wilkins is ...
(Date:11/21/2008)...neral membership of the Medical,Advertising Hall ...heir Annual,Awards Dinner to be held February 10,... Achievement Award will also be given. , Th... of Fame are: , Ronald Pantello, who began his ...dler & Hennessey. In 1980 he left Sudler &...
(Date:11/21/2008)... genetic damage that can lead to disease , ...ar medications for treating attention-deficit hype...age linked to an increased risk for developing can...earchers at Duke University Medical Center and the...s one that reported biomarkers associated with an ...
Breaking Medicine News(10 mins):Health News:New Approach Keeps Tumor Cells From Refueling 2Health News:NursingCenter.com Launches New Features to Improve User Experience 2Health News:NursingCenter.com Launches New Features to Improve User Experience 3Health News:Ronald Pantello, Harry Sweeney, and David Wood Voted Into Medical Advertising Hall of Fame. 2Health News:Ronald Pantello, Harry Sweeney, and David Wood Voted Into Medical Advertising Hall of Fame. 3Health News:ADHD Medications Don't Pose Cancer Risk 2
...pical cyclone Glenda has increased the spread of t...y Valley encephalitis// (MVE), in Western Australi... wet season in Kimberley has spread the virus that.... The cyclone Glenda along with the more recent cy...
...earcher, Professor Ian Frazer of the University of... Premier's Fellowship. The prestigious Fellowship ...r award for his work in developing a vaccine for c...ellowship, Professor Ian Frazer will get $250,000 ...
...eo game makers are now looking to extend their rea...tele is concerned. And a really ripe market awaits... to "Brain Train" concept like a duck to water.// ...s sold 3.3 million of its "Brain Training for Adul...
...ording to a senior Guangdong health official of Ch...this year's peak human bird flu season in the prov...de by other health specialists. The senior health...rector of the Guangdong Centre for Disease Control...
Other Medicine News:
(Date:11/19/2008)...e/ -- Biotech scientists increasingly are applying...etter understand the effects of novel drug candida...c Engineering & Biotechnology News ( GEN ). T...w compound,s mechanism of action and eventually de...ing to the November 15 issue of GEN . ( http://ww...
(Date:11/18/2008)...n more, make a donation or send a Christmas Seals ...USNewswire/ -- Millions will receive Christmas Sea...n Lung Association. These decorative holiday stamp...ng back to 1907 when the Lung Association led effo...ericans alive today have no vivid memories of how ...
(Date:11/18/2008)...gnosed, elderly AML patients , , PRINCETON,...cals today announced that the first patient has be...of CPX-351 (Cytarabine:Daunorubicin) Liposome Inje...id leukemia (AML). , , The first patient wa...al College of Cornell University and New York Pre...
(Date:11/12/2008)...wswire/ -- A new study being,published in this Fri...question, what causes Parkinson,s disease?, One o...rch into,Parkinson,s disease is what causes the se...ce. Answering this question has been especially di...es of brain cells that produce,dopamine and they a...
Breaking Medicine Technology:GEN Reports on the Trend Toward Predictive Toxicogenomics 2American Lung Association Celebrates 101st Annual Christmas Seals Campaign 2Celator(R) Pharmaceuticals Announces Enrollment of First Patient in Phase 2 Study with CPX-351 2Celator(R) Pharmaceuticals Announces Enrollment of First Patient in Phase 2 Study with CPX-351 3A Window Into Parkinson's Disease 2LaVoie Group Adds Cancer Therapeutics Company Neotropix 28R 29 to Its Life Science Agency Roster 26846 1LaVoie Group Adds Cancer Therapeutics Company Neotropix 28R 29 to Its Life Science Agency Roster 26846 2Covance Decides to Pursue Its Original Preclinical Strategy in China 7954 1Covance Decides to Pursue Its Original Preclinical Strategy in China 7954 2Combined Insurance Encourages Women to Assess Insurance Plans and Protection During Breast Cancer Awareness Month 26843 1Combined Insurance Encourages Women to Assess Insurance Plans and Protection During Breast Cancer Awareness Month 26843 2Combined Insurance Encourages Women to Assess Insurance Plans and Protection During Breast Cancer Awareness Month 26843 3Combined Insurance Encourages Women to Assess Insurance Plans and Protection During Breast Cancer Awareness Month 26843 4Austin Dentistry Clinic Now Offers Certified Full Service Sedation Dentistry All Gain No Pain 26841 1Austin Dentistry Clinic Now Offers Certified Full Service Sedation Dentistry All Gain No Pain 26841 2
...ot Study Demonstrates 50% Survival in Valortim-Tre..., March 29, 2007,/PRNewswire-FirstCall/ -- Medarex...d PharmAthene, Inc., a privately held,biotechnolog...se,countermeasures, today announced that Valortim(...didate being developed for the,prevention and trea...
...trations Reached in Key Lung Compartments, REINACH...e-FirstCall/ -- Arpida Ltd. today announced promis... These radiolabelled,Human Microdose studies inclu...groundbreaking study is the first ever using Micro...s in lung compartments.,The results showed that AR...
Other Medicine Technology:Anthrax Monoclonal Antibody Valortim Demonstrates Therapeutic,Effect in New Primate Model of Established Anthrax Infection 2Anthrax Monoclonal Antibody Valortim Demonstrates Therapeutic,Effect in New Primate Model of Established Anthrax Infection 3Anthrax Monoclonal Antibody Valortim Demonstrates Therapeutic,Effect in New Primate Model of Established Anthrax Infection 4Anthrax Monoclonal Antibody Valortim Demonstrates Therapeutic,Effect in New Primate Model of Established Anthrax Infection 5Anthrax Monoclonal Antibody Valortim Demonstrates Therapeutic,Effect in New Primate Model of Established Anthrax Infection 6Anthrax Monoclonal Antibody Valortim Demonstrates Therapeutic,Effect in New Primate Model of Established Anthrax Infection 7Anthrax Monoclonal Antibody Valortim Demonstrates Therapeutic,Effect in New Primate Model of Established Anthrax Infection 8Arpida Announces Promising Results of "First-In-Man" Studies With,AR-709 2Arpida Announces Promising Results of "First-In-Man" Studies With,AR-709 3Arpida Announces Promising Results of "First-In-Man" Studies With,AR-709 4Arpida Announces Promising Results of "First-In-Man" Studies With,AR-709 5
Low-profile, hand-held instrument.
Low-profile, hand-held instrument.
Developed in conjunction with Pierce E. Scranton, Jr., M.D., the Seattle Small Joint Arthroscopy Set offers meticulously designed instrumentation for elbow, foot, and ankle surgeries.
Developed in conjunction with Pierce E. Scranton, Jr., M.D., the Seattle Small Joint Arthroscopy Set offers meticulously designed instrumentation for elbow, foot, and ankle surgeries.
Medicine Products: